CD8A and neoplasm: MiR-128 overexpression, in turn, modulates the percentages of dendritic cells (DCs), CD8 T lymphocytes, and natural killer T cells (NKTs) in tumors and spleens via PDAC zinc-finger E-box-binding homology cassette 1 (ZEB1) thereby enhancing anti-tumor immunity (65).